國新健康(000503.SZ):預計半年度虧損約8921萬元
格隆匯7月14日丨國新健康(000503.SZ)公佈,預計半年度營業收入10,013萬元,虧損約8,921萬元,扣非虧損約8,891萬元。公司業務整體呈現前低後高的季節性特徵,報告期內,公司緊緊圍繞“健康中國”和“三醫協同”改革發展要求,以“三醫協同、創新驅動、數字生態”爲戰略牽引,圍繞醫療衛生行業信息化、數字化、智慧化,以健康大數據的聚、通、用爲主線,聚焦醫保基金綜合管理服務、醫療質量安全服務、藥械監管與藥企服務、健康服務創新,持續挖掘數據價值,不斷優化和完善產品體系。報告期內,營業收入約10,013萬元,預計歸屬於上市公司股東的淨利潤約-8,921萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.